The original and current NICE guidance on the use of donepezil, galantamine and rivastigmine for Alzheimer's disease issued in 2001 recommends the use of these drugs for all patients, with treatment stopping as soon as they no longer have an effect. NICE's review of this guidance initially concluded that there was not enough evidence to support the use of these drugs for all patients as recommended in the original guidance.